WeTrials
Active, not recruiting

Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutaneous (s.c). 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity

What is this study?

This study tests a new combination medication called CagriSema to see how well it helps adults with overweight or obesity lose excess body weight. Researchers want to compare this combination against individual medicines and a placebo, which is an inactive dummy medicine, to find safer and more effective weight management options.

Who can participate?

You may be able to join if you are 18 or older and have a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with a weight-related health condition like high blood pressure or heart disease. People with type 1 or type 2 diabetes cannot participate in this study.

What will happen?

Participants will receive a once-weekly injection under the skin of either the study medicine or a dummy medicine for about a year and a half. After the main study, some participants may join a follow-up extension study to see how their bodies maintain weight without the medication.

Where and when?

This study has multiple locations across the United States, including sites in Alabama and California. The study is currently active but not recruiting new participants at this time.

Key Points
  • 1Testing a new weekly injection called CagriSema for weight loss
  • 2Open to adults with obesity or overweight with related health conditions
  • 3Involves a main treatment period and a follow-up period without medicine

Related video

European Society of Cardiology: lead author Timothy Garvey discusses REDEFINE 1 (November 2025)

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Obesity

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.